Adult Sedation: Oral, Rectal, IM, IV Joseph A
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Legal Rights of Children with Epilepsy in School and Child Care – an Advocate’S Manual
Legal Rights of Children with Epilepsy in School & Child Care AN ADVOCATE’S MANUAL AN ADVOCATE’S AN ADVOCATE’S MANUAL AN ADVOCATE’S First Edition Legal Rights of Children with Epilepsy in School and Child Care – An Advocate’s Manual First Edition Prepared by Leslie Seid Margolis Managing Attorney Maryland Disability Law Center Edited by Gary Gross Director Jeanne A. Carpenter Epilepsy Legal Defense Fund Epilepsy Foundation of America® User is hereby granted permission to copy or disseminate this publication, either in print or electronic format, provided such copies are not made, distributed or used for commercial purposes, and that the user affixes the Epilepsy Foundation’s copyright notice, and states that copying is by permission of the Epilepsy Foundation. To disseminate otherwise, or to republish, requires written permission from the Epilepsy Foundation. Permission can be obtained by contacting the Foundation’s Legal Department at 301-459-3700. The Epilepsy Foundation does not evaluate, promote or endorse commercial products, and nothing contained in this document is intended to be an endorsement of any particular treatment for seizures or epilepsy. © 2008 Epilepsy Foundation of America, Inc. Epilepsy Foundation® and Epilepsy Foundation of America® are registered trademarks of the Epilepsy Foundation of America, Inc. TABLE OF CONTENTS ACKNOWLEDGEMENTS …………………………………………….xiii ABOUT THE AUTHOR ...........................................................................xiv INTRODUCTION …………………………………………………………1 CHAPTER ONE What Do Attorneys -
Rectal Administration of Aid-In-Dying Medications
Rectal Administration of Aid-in-Dying Medications (NOTE: This is a medical procedure and requires a trained clinician who can evaluate the patient for this procedure, do a rectal exam to be sure that the procedure can be safely accomplished, and be responsible for potential complications. We do not recommend that this be done by families alone without significant direct clinician participation.) by Thalia DeWolf, RN, CHPN For questions and/or information, email [email protected] An Essential Warning: Aid-in-dying medications are a thick suspension of powders. They can clog a Macy Catheter. So while Macy Catheters are indeed wonderful and useful devices for end-of- life care, they should not be used for medical aid in dying. See below for proper materials. Pre-care: An intact, empty, warm, moist, well-perfused rectum assures thorough absorption of rectally administered aid-in-dying medications. Be sure your patient has good bowel care in the 72 hours before aid in dying. A daily soft BM is recommended. The best practice is to do an enema the day before or the morning of aid in dying. Within 24 hours of the procedure (or at the time of the procedure) a digital rectal exam must be performed by an experienced clinician (RN or physician) The clinician must ascertain that the lumen is patent and will accept the catheter; that the rectal vault is not filled with stool (small amounts of stool will not interfere with absorption of medications, large amounts, especially of thick, pasty stool, are likely to bind the medications and prevent absorption; that tumor has not invaded the rectum; that the rectum is warm and well-perfused). -
Mucosal Delivery Systems of Antihypertensive Drugs: a Practical Approach in General Practice Lukasz P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Jun; 162(2):71-78. Mucosal delivery systems of antihypertensive drugs: A practical approach in general practice Lukasz P. Bialya,b, Cezary Wojcikc, Izabela Mlynarczuk-Bialya,b Patients who are unable to receive oral medication (p.o.) are a major problem in outpatient settings, especially in home health care systems. Mucosal administration of drugs offers an alternative to the oral route, especially when the parenteral mode cannot be used. There are three main pathways of mucosal administration: sublingual/buccal, intranasal and rectal. We discuss the possibility of mucosal delivery of antihypertensive drugs. Perindopril arginine and Amlodipine besylate are registered in the EU as orodispersible tablets for oromucosal delivery, however, they are not available in all countries. For this reason, we describe other drugs suitable for mucosal delivery: Captopril and Nitrendipine in the sublingual system and Metoprolol tartrate, Propranolol and Furosemide by the transrectal route. Based on the published data and common clinical practice we discuss the use of mucosal delivery systems of all these antihypertensive drugs with special attention to their pharmacokinetics. We illustrate this mini-review with a case report of the prolonged-term use of mucosal delivery of sublingual Captopril and Nitrendipine combined with rectal Metoprolol tartrate and Furosemide in a patient with severe hypertension unable to receive medication p.o. This is also a report on the first human use of Furosemide-containing suppositories as well as prolonged-term transmucosal administration of these four drugs, describing a practical approach leading to successful control of severe hyperten- sion with four antihypertensive drugs delivered via the mucosal route. -
Systematic Desensitization to Venipuncture with Combined Visual Supports and Relaxation Strategies for an Adult with Developmental Disability
4/13/2015 Systematic Desensitization to Venipuncture with Combined Visual Supports and Relaxation Strategies for an Adult with Developmental Disability Jessica Fox, M.ADS, Sr. Behaviour Therapist, Children & Youth Program Kimberley Taylor, M.ADS, BCBA, Sr. Behaviour Therapist, Adults Program Leeping Tao, RN (EC), MN, Nurse Practitioner, Adults Program Client Profile ● 24 year old male ● Diagnosis: Chromosome Ring 13 syndrome, moderate developmental disability, sickle cell trait, and small kidneys ● Resides at home with his Mother and attends a day program 3 days per week Interdisciplinary Approach & Clinical Service History ● Previous family and individual counselling due to death of young nephew ● Behaviour therapy to target aggression toward others in day program and home, as well as elopement in community ● Nursing and medical support through primary care clinic with Dr. Bill Sullivan at St. Michael’s Hospital 1 4/13/2015 Group Activity – How do you feel? Risks to client & current needs ● Due to small kidneys and having an elevated creatine levels he required ongoing blood work ● Long learning history of a fear of needles and having blood drawn ● Aggression toward others with blood being drawn, as well as anxiety-related behaviour ● Ativan was trialed as a PRN, however unsuccessful ● Required the least intrusive intervention over long term to appropriately support client What does the research tell us about phobias? ● Ost and Sterner (1987) report that blood phobia, including injuries, is one of the most common phobias in the general -
Blood Tests for People with Learning Disabilities: Making Reasonable Adjustments
Blood tests for people with learning disabilities: making reasonable adjustments Blood tests for people with learning disabilities: making reasonable adjustments About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health, and are a distinct delivery organisation with operational autonomy to advise and support government, local authorities and the NHS in a professionally independent manner. About the Public Health England Learning Disabilities Observatory The Public Health England Learning Disabilities Observatory (PHELDO) was set up in April 2010 to provide high quality data and information about the health and healthcare of people with learning disabilities. We are also known as Improving Health and Lives (IHaL). This name was suggested for the Observatory at a consultation with self-advocates organised for the Department of Health by Mencap. The information helps commissioners and providers of health and social care to understand the needs of people with learning disabilities, their families and carers, and, ultimately, to deliver better healthcare. PHELDO is a collaboration between PHE, the Centre for Disability Research at Lancaster University and the National Development Team for Inclusion. Since April 2013, the Observatory has been operated by PHE. Public Health England Wellington House, 133-155 Waterloo Road, London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk, Facebook: www.facebook.com/PublicHealthEngland Prepared by: Anna Marriott For queries relating to this document, please contact: [email protected] © Crown copyright 2017 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. -
Diazepam Rectal Gel (Diastat) Administration
LOS ANGELES UNIFIED SCHOOL DISTRICT Student Health and Human Services Division District Nursing Services DIAZEPAM RECTAL GEL (DIASTAT) ADMINISTRATION I. GENERAL GUIDELINES A. PURPOSE 1. To control acute, repetitive or prolonged seizures. 2. To prevent status epilepticus, a life-threatening condition in which seizures are continuous. 3. To administer Diastat safely and in a timely manner. B. GENERAL INFORMATION 1. Diazepam rectal gel (Diastat) is an “emergency anti-seizure medication” approved by Food and Drug Administration (FDA). Education Code 49414.7 allows unlicensed school staff to administer emergency anti-seizure medication to students with acute, prolonged or repetitive seizure 2. Licensed healthcare provider and parent authorizations for medication must be completed and signed. Healthcare Provider Authorization must specify student specific seizure symptoms, including frequency, type, duration, medication dosage, potential side effects and instructions when to call the paramedics. 3. Diastat training must be student specific- demonstration. Verbalization of the following by the trainee will occur upon completion of the training: a. Identification of characteristics of student’s seizures b. Understanding of Diastat order from the licensed healthcare provider c. Location, storage and disposal of Diastat d. Appropriate steps of administration of Diastat e. Care of the student before, during and after the administration of Diastat f. Documentation of Diastat administration 4. Parent/guardian must notify the school if Diastat was administered within the past 4 hours on a school day. C. PERSONNEL 1. School nurse or school physician 2. Designated school personnel who possess current First Aid and CPR Certification and are trained by the school nurse or the school physician. -
The Fear of Needles: a Systematic Review and Meta-Analysis
DR MARY A.M. ROGERS (Orcid ID : 0000-0001-5519-3223) Article type : Review FULL TITLE: The Fear of Needles: A Systematic Review and Meta-Analysis RUNNING HEAD: Fear of Needles AUTHORS: Jennifer MCLENON, BS1 Mary A.M. ROGERS, PhD, MS2 JOB TITLES & AFFILIATION: 1. Graduate Student, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA 2. Research Associate Professor, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA CORRESPONDENCE: Mary A·M. Rogers, PhD Research Associate Professor Department of Internal Medicine University Author Manuscript of Michigan Building 16, Room 422W North Campus Research Complex This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/JAN.13818 This article is protected by copyright. All rights reserved 2 2800 Plymouth Road Ann Arbor, Michigan, USA 48109-2800 Telephone: 734-647-8851 FAX: 734-936-8944 Email: maryroge@umich·edu CONFLICT OF INTEREST: No conflict of interest has been declared by the authors. FUNDING: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. ABSTRACT Aims: To evaluate the prevalence of needle fear and summarize the characteristics of individuals who exhibit this fear. Background: Injections are among the most common medical procedures, yet fear of needles can result in avoidance of preventive measures and treatment. Design: Systematic review and meta-analysis. Data Sources: MEDLINE (1966-2017), Embase (1947-2017), PsycINFO (1967-2017) and CINAHL (1961-2017) were searched, with no restrictions by age, gender, race, language, or country. -
Intramuscular and Rectal Therapies of Acute Seizures
Epilepsy & Behavior 49 (2015) 307–312 Contents lists available at ScienceDirect Epilepsy & Behavior journal homepage: www.elsevier.com/locate/yebeh Review Intramuscular and rectal therapies of acute seizures Ilo E. Leppik a,b,c,⁎,SimaI.Patelb,c a Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA b MINCEP Epilepsy Care, University of Minnesota Physicians, Minneapolis, MN, USA c Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA article info abstract Article history: The intramuscular (IM) and rectal routes are alternative routes of delivery for antiepileptic drugs (AEDs) Accepted 1 May 2015 when the intravenous route is not practical or possible. For treatment of acute seizures, the AED used should Available online 11 June 2015 have a short time to maximum concentration (Tmax). Some AEDs have preparations that may be given intramus- cularly. These include the benzodiazepines (diazepam, lorazepam, and midazolam) and others (fosphenytoin, le- Keywords: vetiracetam). Although phenytoin and valproate have parenteral preparations, these should not be given Intramuscular intramuscularly. A recent study of prehospital treatment of status epilepticus evaluated a midazolam (MDZ) Rectal Acute seizures autoinjector delivering IM drug compared to IV lorazepam (LZP). Seizures were absent on arrival to the emergen- Antiepileptic drugs cy department in 73.4% of the IM MDZ compared to a 63.4% response in LZP-treated subjects (p b 0.001 for supe- riority). Almost all AEDs have been evaluated for rectal administration as solutions, gels, and suppositories. In a placebo-controlled study, diazepam (DZP) was administered at home by caregivers in doses that ranged from 0.2 to 0.5 mg/kg. -
Hypotonic Delivery of Drugs and Drug-Loaded Nanoparticles to the Gastrointestinal Tract
HYPOTONIC DELIVERY OF DRUGS AND DRUG-LOADED NANOPARTICLES TO THE GASTROINTESTINAL TRACT By Katharina Maisel A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland December, 2014 © 2014 Katharina Maisel All Rights Reserved ABSTRACT Innovative gastrointestinal (GI) drug delivery vehicles such as mucus penetrating nanoparticles (MPP) and fluid-absorption inducing (hypotonic) delivery vehicles have potential to improve therapeutic outcomes over conventional methods such as mucoadhesive particles (MAP) for GI diseases, including ulcerative colitis (UC) and HIV pre-exposure prophylaxis (PrEP). More than 80% of all drugs are absorbed via the GI tract for either systemic or local treatment. MAP delivered to the GI tract are thought to improve oral absorption or local targeting of difficult-to-deliver drug classes. Mucus is a continuously secreted barrier that effectively traps foreign particulates to protect the underlying epithelium. Rapid clearance of the most superficial luminal mucus layers in the GI tract may limit the effectiveness of MAP. Here, I test the current dogma of mucoadhesion by comparing MAP and MPP GI drug delivery via the oral and rectal routes. In addition I investigate the development of several vehicles including rectal enemas and gels for more effective delivery of nanocarriers or free drugs. First, I illustrate that MPP uniformly coat all surfaces of the GI epithelium, while MAP aggregated in mucus in the center of the lumen, far away from the absorptive epithelium, both in healthy mice and mice with UC. In the mouse colorectum, MPP penetrated into mucus in the deeply in-folded surfaces to evenly coat the entire epithelial surface. -
Achievements in Thermosensitive Gelling Systems for Rectal Administration
International Journal of Molecular Sciences Review Achievements in Thermosensitive Gelling Systems for Rectal Administration Maria Bialik, Marzena Kuras, Marcin Sobczak and Ewa Oledzka * Department of Biomaterials Chemistry, Chair of Analytical Chemistry and Biomaterials, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha St., 02-097 Warsaw, Poland; [email protected] (M.B.); [email protected] (M.K.); [email protected] (M.S.) * Correspondence: [email protected]; Tel.: +48-22-572-07-55 Abstract: Rectal drug delivery is an effective alternative to oral and parenteral treatments. This route allows for both local and systemic drug therapy. Traditional rectal dosage formulations have histori- cally been used for localised treatments, including laxatives, hemorrhoid therapy and antipyretics. However, this form of drug dosage often feels alien and uncomfortable to a patient, encouraging refusal. The limitations of conventional solid suppositories can be overcome by creating a thermosen- sitive liquid suppository. Unfortunately, there are currently only a few studies describing their use in therapy. However, recent trends indicate an increase in the development of this modern therapeutic system. This review introduces a novel rectal drug delivery system with the goal of summarising recent developments in thermosensitive liquid suppositories for analgesic, anticancer, antiemetic, antihypertensive, psychiatric, antiallergic, anaesthetic, antimalarial drugs and insulin. The report also presents the impact of various types of components and their concentration on the properties of this rectal dosage form. Further research into such formulations is certainly needed in order to meet Citation: Bialik, M.; Kuras, M.; the high demand for modern, efficient rectal gelling systems. Continued research and development Sobczak, M.; Oledzka, E. -
KAYEXALATE (Sodium Polystyrene Sulfonate) Is a Cream Or Light Brown Fine Powder of Sodium Polystyrene Sulfonate
PRESCRIBING INFORMATION ® PrKAYEXALATE (Sodium Polystyrene Sulfonate) Cation - Exchange Resin sanofi-aventis Canada Inc. Date of Revision: 2905 Place Louis R.-Renaud September 19, 2018 Laval, Quebec H7V 0A3 Submission Control No.: 217331 s-a Version 5.0 dated September 19, 2018 KAYEXALATE Prescribing Information Page 1 of 12 DESCRIPTION KAYEXALATE (sodium polystyrene sulfonate) is a cream or light brown fine powder of sodium polystyrene sulfonate. KAYEXALATE is a cation-exchange resin prepared in the sodium phase, with an in vivo exchange capacity of approximately 1 mmol (in vitro approximately 3.1 mmol) of potassium per gram. The sodium content is approximately 4.1 mmol (100 mg) per gram of the drug. KAYEXALATE can be administered either orally or as an enema. ACTION Sodium polystyrene sulfonate is not absorbed from the gastrointestinal tract. As the resin passes through the gastrointestinal tract, the resin removes the potassium ions by exchanging it for sodium ions. Most of this action occurs in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. Potassium exchange also occurs in the colon following retention of the resin, when administered as an enema. The efficiency of this process is limited and unpredictable. It commonly approximates the order of 33 per cent but the range is so large that definite indices of electrolyte balance must be clearly monitored. Metabolic data are unavailable. INDICATION KAYEXALATE is indicated for the treatment of hyperkalemia. CONTRAINDICATIONS KAYEXALATE should not be administered to patients with the following conditions: • serum potassium <5 mmol/L • history of hypersensitivity to polystyrene sulfonate resins • obstructive bowel disease KAYEXALATE should not be administered orally to neonates or in neonates with reduced gut motility (postoperatively or drug induced). -
Dismantling a Cognitive-Behavioural Treatment for Chronically Ill Children
Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author. “Stupid Little Pointy Needle!” Dismantling a Cognitive-Behavioural Treatment for Chronically Ill Children with Needle-Related Distress A thesis presented in partial fulfilment of the requirements for the degree of Doctorate in Clinical Psychology at Massey University, Wellington New Zealand. Ψ Jessica Anne McIvor 2014 Abstract For some chronically ill children, having an injection is a regular occurrence and can result in distress and avoidance behaviour for the child and their family. There can also be negative health implications of these children not having their injections. Research supports the effectiveness of various cognitive-behavioural therapy (CBT) packages for childhood needle- related distress (NRD), although which components are most effective has yet to be identified. The aim of the present study was to replicate previous research findings from McIvor (2011), by dismantling an existing manualised CBT package to determine whether cognitive and/or behavioural components were necessary for a reduction in NRD. Three treatment manuals were used to conduct this research, namely (1) a CBT manual (6 sessions), (2) a cognitive therapy (CT, 4 sessions) manual, and (3) a behavioural therapy (BT, 4 sessions) manual. Treatments were evaluated using a multiple-baseline across participants single-case design. Twelve children aged 7-13 of New Zealand European/Pākehā and Māori descent were randomly allocated to one of the three treatment conditions, with four children and their carers assigned to each condition.